Recent searches
Search options
Administered by:
If the #USTaxpayers invested in #Bedaquiline, we need to sue #JnJ (Johnson & Johnson) for the generic access just like we did for #Truvada! @aoc.
https://www.washingtonpost.com/opinions/2023/05/16/multidrug-resistant-tuberculosis-treatment/
The Washington PostWhy is a curable disease still allowed to kill millions?
William Canna-bass @JizzelEtBass@kolektiva.social
The #USTaxpayers invested up to $1.2 Billion, #BillionDollars, in #Bedaquiline out spending #JnJ by up to a factor of 5:1 (#Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500616/#pone.0239118.s001)
Where is our #ROI if the patent office approves their clinically insignificant formulation tweak and extends their patent?
PubMed Central (PMC)Public investments in the clinical development of bedaquilineIn 2012, bedaquiline became the first new treatment from a novel class to be approved for tuberculosis in nearly five decades and is now a core component of the standard of care for multidrug-resistant tuberculosis. In addition to the originator pharmaceutical ...